Mahanine mediated therapeutic inhibition of estrogen receptor-α and CDK4/6 expression, decipher the chemoprevention-signaling cascade in preclinical model of breast cancer

被引:3
|
作者
Samanta, Suman Kumar [1 ,2 ]
Choudhury, Paramita [2 ,3 ]
Kandimalla, Raghuram [2 ,4 ,5 ]
Aqil, Farrukh [4 ,6 ]
Moholkar, Disha N. [4 ,5 ]
Gupta, Ramesh C. [4 ,5 ]
Das, Momita [2 ]
Gogoi, Bhaskarjyoti [7 ]
Gogoi, Neelutpal [8 ]
Sarma, Partha Pratim [2 ]
Devi, Rajlakshmi [2 ]
Talukdar, Narayan C. [1 ]
机构
[1] Assam Down Town Univ, Fac Sci, Gauhati 781026, Assam, India
[2] Inst Adv Study Sci & Technol, Life Sci Div, Tradit & Modern Drug Discovery & Dis Diag Lab, Gauhati 781035, Assam, India
[3] Gauhati Univ, Dept Zool, Gauhati 781014, Assam, India
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40202 USA
[5] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA
[6] Univ Louisville, Dept Med, Louisville, KY 40202 USA
[7] Assam Royal Global Univ, Dept Biotechnol, Gauhati 781035, Assam, India
[8] Dibrugarh Univ, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India
关键词
Murraya koenigii; Mahanine; Breast cancer; Chemoprevention; ER alpha antagonist; CDK4/6; inhibitor; LEPTIN; RESISTANCE; GROWTH; CELLS; RNA;
D O I
10.1016/j.jep.2023.117235
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Mahanine (MH), a naturally occurring carbazole alkaloid, isolated from Ayurvedic medicinal plant Murraya koenigii (L.) Spreng, has been shown to have various pharmacological properties, including its inhibitory activity against different breast cancers (BC) subtypes.Aim of the study: While MH triggers apoptosis in BC cells regardless of subtype, the specific mechanism of MH action is not fully understood. In this study, we show the effect of MH in preventing BC progression by inducing apoptosis in relation to estrogen receptor-alpha (ER alpha) and cell cycle regulatory proteins.Materials and methods: To assess the pharmacological activity in various in vitro and in vivo tests, isolated and pure MH was used. To conclude the study, cutting edged molecular biology techniques including Western blot analysis, enzyme-linked immunosorbent assay (ELISA), molecular simulation study, and other related software analysis were employed.Results: MH demonstrated dose dependent cell viability against drug sensitive (MCF-7 and MDA-MB-231) and paclitaxel resistant (MCF-7TR and MDA-MB-231TR) BC cells. MH also exhibited synergistic activity with tamoxifen (TAM) against estrogen receptor positive (ER+) BC cells by inhibiting ER alpha expression in MCF-7 cells and N-Methyl-N-nitrosourea (MNU)-induced mammary tumor in a dose-dependent manner while having no effect on vinculin expression. In addition, MH inhibited cell cycle regulatory genes namely CDK1/CDK4/CDK6/ CDC25A and neo-angiogenesis through downregulation of CD31/PECAMs in MCF-7, MDA-MB-231 cells and mammary tumors from MNU-induced rats. MH therapy has been shown to be significantly able to lower the serum leptin level and to be beneficial against the initiation of tumor development in SD rats for up to 12 weeks. Molecular modeling study revealed that MH has antagonized the effectiveness of several types of estrogen those bind to the ER alpha and has comparable binding efficacy to TAM.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer
    Michaloglou, Chrysiis
    Crafter, Claire
    Siersbaek, Rasmus
    Delpuech, Oona
    Curwen, Jon O.
    Carnevalli, Larissa S.
    Staniszewska, Anna D.
    Polanska, Urszula M.
    Cheraghchi-Bashi, Azadeh
    Lawson, Mandy
    Chernukhin, Igor
    McEwen, Robert
    Carroll, Jason S.
    Cosulich, Sabina C.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 908 - 920
  • [42] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [43] CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer
    Alves, C.
    Elias, D.
    Lyng, M.
    Bak, M.
    Lykkesfeldt, A.
    Ditzel, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S118 - S118
  • [44] Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
    Palafox, M.
    Herrera, M. T.
    Bellet, M.
    Arribas, J.
    Saura, C.
    Di Tomaso, E.
    Turner, N. C.
    Cortes, J.
    Baselga, J.
    Serra, V.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S134 - S134
  • [45] CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer
    Liu, Wenqiang
    Zhang, Ruhua
    Yu, Xinhao
    Zhang, Yu
    Kang, Tiebang
    Liao, Dan
    MEDICAL ONCOLOGY, 2023, 40 (09)
  • [46] CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer
    Wenqiang Liu
    Ruhua Zhang
    Xinhao Yu
    Yu Zhang
    Tiebang Kang
    Dan Liao
    Medical Oncology, 40
  • [47] Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
    Serra, Violeta
    Palafox, Marta
    Herrera, Maria-Teresa
    Rivas, Martin A.
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Oliveira, Mafalda
    Saura, Cristina
    di Tomaso, Emmanuelle
    Camponigro, Giordi
    Turner, Nicholas C.
    Cortes, Javier
    Baselga, Jose
    CANCER RESEARCH, 2016, 76
  • [48] Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer
    Chica-Parrado, Maria Rosario
    Kim, Gun Min
    Uemoto, Yasuaki
    Napolitano, Fabiana
    Lin, Chang-Ching
    Ye, Dan
    Bikorimana, Emmanuel
    Fang, Yisheng
    Lee, Kyung-min
    Mendiratta, Saurabh
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER LETTERS, 2024, 604
  • [49] CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR plus MBC) with ESR1 mutations and fusions
    Brett, Jamie O.
    Weipert, Caroline M.
    Ritterhouse, Lauren L.
    Zhang, Nicole
    Yu, Junhua
    Ryan, Lianne Y.
    Spring, Laura M.
    Rivera, Miguel N.
    Lennerz, Jochen K.
    Dias-Santagata, Dora
    Ellisen, Leif W.
    Bardia, Aditya
    Wander, Seth A.
    CANCER RESEARCH, 2022, 82 (12)
  • [50] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70